Personal fairness agency Accelmed Companions lately closed a $400 million oversubscribed second fund. The Florida-based agency invests in health-tech corporations with revenues between $20 million and $70 million.
Accelmed’s technique entails working with middle-market corporations which have a industrial product, and serving to them develop, or in some circumstances, including on different applied sciences. Its portfolio consists of medical system corporations, diagnostics and digital well being corporations.
“Over the previous decade, we’ve got served as a trusted value-add associate to health-tech corporations and administration groups who wish to take their companies to the subsequent degree however lack the sources and experience to execute on these aspirations on their very own,” Founder and Managing Companion Uri Geiger stated in a information launch. “The outcome has been broader entry to progressive health-tech options and a portfolio of high-growth companies which have confirmed resilient to the Covid pandemic.”
To date, Accelmed has already made three investments from its new fund. The corporate lately invested $40 million into MedMinder, a startup constructing a touchscreen-enabled capsule dispenser the place customers can order a month’s price of medicines organized by day. The dispenser “unlocks” when it’s time for them to take their drugs.
Its different current investments embrace NeuroPace, an organization making an implanted system for epileptic seizures, and TearLab, an organization making a check to diagnose dry eye illness. Accelmed acquired TearLab together with its $25 million funding.
Picture credit score: StockFinland, Getty Photographs